Skin irritation

Skin irritation is not a specific molecule, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it refers to a clinical symptom characterized by redness, itching, burning sensation, and sometimes swelling or lesions on the skin. Skin irritation can result from various causes including physical damage to the skin barrier; exposure to irritants; immune-mediated inflammation; and activation of sensory nerve fibers that mediate itch and pain responses[2]. The biological mechanisms underlying skin inflammation and itch involve complex interactions between keratinocytes (skin cells), immune cells releasing cytokines like interleukin 17 (IL-17), histamine release from mast cells activating sensory nerves via receptors such as protease activated receptor 2/4 and Mas-related G protein-coupled receptors[1][2][3]. While drugs may alleviate symptoms by targeting these pathways—such as anti-inflammatory agents blocking IL-17 signaling in psoriasis—“skin irritation” itself does not represent an actionable molecular entity. In summary: Skin irritation is not a valid therapeutic target but rather describes a clinical phenomenon resulting from multiple possible molecular mechanisms. For structured data purposes it should be flagged as incorrect for use as a canonical drug target.

Other names

Skin irritationIrritant dermatitis (in some contexts)Cutaneous irritation (in some contexts)